Xolair denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Xolair (omalizumab) as Experimental — and Why This Is Appealable

An "experimental or investigational" denial for Xolair is most commonly issued when the drug is being prescribed for a use that does not appear in UHC's coverage policy as an approved indication, or when the claim coding does not clearly align with an FDA-approved use. For Xolair's established FDA-approved indications (which include allergic asthma, chronic idiopathic urticaria, and nasal polyps, among others depending on the current label), an experimental denial may represent a coverage policy lag, a diagnosis-code mismatch, or a request for an off-label use that requires a different evidentiary showing.

If the prescribed use is on-label, this denial is among the most straightforward to overturn. If the use is off-label, the appeal requires demonstrating that the use is supported by authoritative published evidence and guideline recommendations.

## Your Appeal Rights

• Internal appeal (ERISA §503): File a written internal appeal documenting the FDA-approved status of the prescribed use.
• External review (ACA §2719): If denied internally, independent external review is available. File within the four-month window from the final internal denial. The external reviewer is not bound by UHC's internal criteria.
• Expedited review: Available when delay would jeopardize health or the ability to regain maximum function.

## Documentation to Gather

1. FDA prescribing label — obtain the current label from Drugs@FDA and highlight every approved indication. Confirm whether the prescribed use falls within an approved indication. 2. Diagnosis documentation — chart notes, diagnostic test results, and the ICD-10 code used on the claim; confirm alignment with the FDA-approved indication language. 3. UHC coverage policy — obtain UHC's current coverage determination policy for Xolair; identify the specific language used to classify the use as experimental. 4. Prescriber medical-necessity and scientific-support letter — for on-label use, the prescriber should affirm FDA approval and clinical appropriateness. For off-label use, the prescriber should cite the relevant guideline organization and supporting evidence categories (peer-reviewed literature, major guideline endorsement). 5. Applicable guideline reference — reference the relevant professional society (e.g., the applicable AAAAI or GINA guideline) by organization name only; do not reproduce specific statistics.

## Criteria-Mapping Structure

| UHC Experimental Denial Basis | Your Rebuttal | |---|---| | Use not FDA-approved | FDA label with approved indication highlighted | | Use not in UHC coverage policy | UHC policy text + prescriber letter mapping clinical facts to policy criteria | | Insufficient evidence basis | Guideline organization citation + prescriber support letter |

If this is an on-label denial, lead with the FDA label — external reviewers routinely overturn experimental denials for approved indications.